PT  - JOURNAL ARTICLE
AU  - Rodrigues, Tamara S.
AU  - de Sá, Keyla S.G.
AU  - Ishimoto, Adriene Y.
AU  - Becerra, Amanda
AU  - Oliveira, Samuel
AU  - Almeida, Leticia
AU  - Gonçalves, Augusto V.
AU  - Perucello, Debora B.
AU  - Andrade, Warrison A.
AU  - Castro, Ricardo
AU  - Veras, Flavio P.
AU  - Toller-Kawahisa, Juliana E.
AU  - Nascimento, Daniele C.
AU  - de Lima, Mikhael H.F.
AU  - Silva, Camila M. S.
AU  - Caetite, Diego B.
AU  - Martins, Ronaldo B.
AU  - Castro, Italo A.
AU  - Pontelli, Marjorie C.
AU  - de Barros, Fabio C.
AU  - do Amaral, Natália B.
AU  - Giannini, Marcela C.
AU  - Bonjorno, Letícia P.
AU  - Lopes, Maria Isabel F.
AU  - Benatti, Maíra N.
AU  - Santana, Rodrigo C.
AU  - Vilar, Fernando C.
AU  - Auxiliadora-Martins, Maria
AU  - Luppino-Assad, Rodrigo
AU  - de Almeida, Sergio C.L.
AU  - de Oliveira, Fabiola R.
AU  - Batah, Sabrina S.
AU  - Siyuan, Li
AU  - Benatti, Maira N.
AU  - Cunha, Thiago M.
AU  - Alves-Filho, José C.
AU  - Cunha, Fernando Q.
AU  - Cunha, Larissa D.
AU  - Frantz, Fabiani G.
AU  - Kohlsdorf, Tiana
AU  - Fabro, Alexandre T.
AU  - Arruda, Eurico
AU  - de Oliveira, Renê D.R.
AU  - Louzada-Junior, Paulo
AU  - Zamboni, Dario S.
TI  - Inflammasome activation in COVID-19 patients
AID  - 10.1101/2020.08.05.20168872
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.05.20168872
4099  - http://medrxiv.org/content/early/2020/08/06/2020.08.05.20168872.short
4100  - http://medrxiv.org/content/early/2020/08/06/2020.08.05.20168872.full
AB  - Severe cases of COVID-19 are characterized by a strong inflammatory process that may ultimately lead to organ failure and patient death. The NLRP3 inflammasome is a molecular platform that promotes inflammation via cleavage and activation of key inflammatory molecules including active caspase-1 (Casp1p20), IL-1β and IL-18. Although the participation of the inflammasome in COVID-19 has been highly speculated, the inflammasome activation and participation in the outcome of the disease is unknown. Here we demonstrate that the NLRP3 inflammasome is activated in response to SARS-CoV-2 infection and it is active in COVID-19, influencing the clinical outcome of the disease. Studying moderate and severe COVID-19 patients, we found active NLRP3 inflammasome in PBMCs and tissues of post-mortem patients upon autopsy. Inflammasome-derived products such as Casp1p20 and IL-18 in the sera correlated with the markers of COVID-19 severity, including IL-6 and LDH. Moreover, higher levels of IL-18 and Casp1p20 are associated with disease severity and poor clinical outcome. Our results suggest that the inflammasome is key in the pathophysiology of the disease, indicating this platform as a marker of disease severity and a potential therapeutic target for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFAPESP grants (2013/08216-2, 2019/11342-6 and 2020/04964-8), CNPq and CAPES grants.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The procedures followed in the study were approved by the National Ethics Committee, Brazil (CONEP, CAAE: 30248420.9.0000.5440). Written informed consent was obtained from recruited patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study will be made available upon request or in public repositories.